Foundry Partners LLC Takes $10.04 Million Position in Evolent Health, Inc. (NYSE:EVH)

Foundry Partners LLC bought a new position in shares of Evolent Health, Inc. (NYSE:EVH) in the third quarter, Holdings Channel.com reports. The institutional investor bought 355,098 shares of the technology company’s stock, valued at approximately $10,042,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of EVH. Vanguard Group Inc. lifted its holdings in shares of Evolent Health by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 10,915,070 shares of the technology company’s stock valued at $357,905,000 after buying an additional 93,739 shares during the period. American International Group Inc. grew its stake in shares of Evolent Health by 1.2% during the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock worth $1,817,000 after purchasing an additional 640 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Evolent Health by 8.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 39,522 shares of the technology company’s stock valued at $1,297,000 after purchasing an additional 3,064 shares in the last quarter. Natixis acquired a new position in shares of Evolent Health in the 1st quarter valued at $1,328,000. Finally, Gabelli Funds LLC boosted its holdings in Evolent Health by 21.5% during the first quarter. Gabelli Funds LLC now owns 638,500 shares of the technology company’s stock worth $20,936,000 after buying an additional 113,000 shares in the last quarter.

Evolent Health Stock Performance

Shares of EVH stock opened at $11.29 on Thursday. Evolent Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock’s fifty day moving average is $24.00 and its two-hundred day moving average is $23.99.

Wall Street Analysts Forecast Growth

EVH has been the subject of a number of recent analyst reports. JMP Securities cut their price objective on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Barclays cut their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Oppenheimer lowered their price target on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research report on Monday. KeyCorp started coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, Truist Financial reaffirmed a “buy” rating and set a $33.00 target price on shares of Evolent Health in a research note on Tuesday, August 27th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $28.90.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.